Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers

Open access
Möhrmann, Lino, Huang, Helen J., Hong, David S., Tsimberidou, Apostolia M., Fu, Siqing, Piha-Paul, Sarina A., Subbiah, Vivek, Karp, Daniel D., Naing, Aung, Krug, Anne, Enderle, Daniel, Priewasser, Tina, Noerholm, Mikkel, Eitan, Erez, Coticchia, Christine, Stoll, Georg, Jordan, Lisa-Marie, Eng, Cathy, Kopetz, E. Scott, Skog, Johan, Meric-Bernstam, Funda, Janku, Filip · 2018 · Clinical Cancer Research

Abstract

Purpose: Blood-based liquid biopsies offer easy access to genomic material for molecular diagnostics in cancer. Commonly used cell-free DNA (cfDNA) originates from dying cells. Exosomal nucleic acids (exoNAs) originate from living cells, which can better reflect underlying cancer biology. Experimental Design: Next-generation sequencing (NGS) was used to test exoNA, and droplet digital PCR (ddPCR) and BEAMing PCR were used to test cfDNA for BRAFV600, KRASG12/G13, and EGFRexon19del/L858R mutations in 43 patients with progressing advanced cancers. Results were compared with clinical testing of archival tumor tissue and clinical outcomes. Results: Forty-one patients had BRAF, KRAS, or EGFR mutations in tumor tissue. These mutations were detected by NGS in 95% of plasma exoNA samples, by ddPCR in 92% of cfDNA samples, and by BEAMing in 97% cfDNA samples. NGS of exoNA did not detect any mutations not present in tumor, whereas ddPCR and BEAMing detected one and two such mutations, respectively. Compared with patients with high exoNA mutation allelic frequency (MAF), patients with low MAF had longer median survival (11.8 vs. 5.9 months; P = 0.006) and time to treatment failure (7.4 vs. 2.3 months; P = 0.009). A low amount of exoNA was associated with partial response and stable disease ≥6 months (P = 0.006). Conclusions: NGS of plasma exoNA for common BRAF, KRAS, and EGFR mutations has high sensitivity compared with clinical testing of archival tumor and testing of plasma cfDNA. Low exoNA MAF is an independent prognostic factor for longer survival. Clin Cancer Res; 24(1); 181–8. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2007

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 166

Metadata

Authors
Möhrmann, L., Huang, H. J., Hong, D. S., Tsimberidou, A. M., Fu, S., Piha-Paul, S. A., Subbiah, V., Karp, D. D., Naing, A., Krug, A., Enderle, D., Priewasser, T., Noerholm, M., Eitan, E., Coticchia, C., Stoll, G., Jordan, L.-M., Eng, C., Kopetz, E. S., Skog, J., Meric-Bernstam, F., & Janku, F.
Venue
Clinical Cancer Research
Published
2018-01-01
Volume
24
Issue
1
Pages
181-188
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2765899133
Cited by
166
References
6
FWCI
4.67
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-2007
The paper
Möhrmann, L., Huang, H. J., Hong, D. S., Tsimberidou, A. M., Fu, S., Piha-Paul, S. A., Subbiah, V., Karp, D. D., Naing, A., Krug, A., Enderle, D., Priewasser, T., Noerholm, M., Eitan, E., Coticchia, C., Stoll, G., Jordan, L.-M., Eng, C., Kopetz, E. S., . . . Janku, F. (2018). Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-2007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.